Samsung Biologics Co.,Ltd.
KSE 207940.KS
Samsung Biologics Co.,Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023: 10.11%
-
Samsung Biologics Co.,Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 8.43%, a 2.96% change year over year.
-
Samsung Biologics Co.,Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 8.19%, a 59.40% change year over year.
-
Samsung Biologics Co.,Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 5.14%, a 148.18% change year over year.
-
Samsung Biologics Co.,Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 2.07%, a -65.77% change year over year.
| Date | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio | Return on Common Equity |
|---|
| CEO | Mr. John Chongbo Rim |
| IPO Date | Nov. 11, 2016 |
| Location | South Korea |
| Headquarters | 300, Songdo Bio-daero |
| Employees | 4,523 |
| Sector | Health Care |
| Industries | |
Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Past 5 years
USD 25.13
USD 137.76
USD 125.83
USD 161.29
USD 151.40
StockViz Staff
January 15, 2025
Any question? Send us an email